Investors
Stock Quote
ICCC Stock Price
Data provided by Yahoo Finance. Prices may be delayed. Not financial advice.
Press Releases
Recent News | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014
SEC Filings
SEC Filings
Annual Report and Proxy
Corporate
Governance
ICCC Code of Conduct
Charter and Powers of the Audit Committee
Nominating Committee Charter
Management & Directors
2022 Press Releases
11-21-22 ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2022
11-10-22 ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2022
10-05-22 ImmuCell Announces Preliminary, Unaudited Sales Results for Third Quarter of 2022
09-14-22 ImmuCell to Participate in the Lytham Partners Fall 2022 Investor Conference
08-11-22 ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2022
08-04-22 ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2022
07-27-22 ImmuCell Receives Technical Section Incomplete Letter from FDA Pertaining to Re-Tain®
07-07-22 ImmuCell Announces Preliminary, Unaudited Sales Results for Second Quarter of 2022
05-19-22 ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders
05-12-22 ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2022
05-10-22 ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2022
05-05-22 Dr. Mark Wustenberg joins ImmuCell as Commercial Leader of Stakeholder Engagement
04-11-22 ImmuCell Announces Record Preliminary, Unaudited Sales Results for First Quarter of 2022
Company Contact
Olivier te Boekhorst
President & CEO
investor.relations@immucell.com
Investor Contact
Lytham Partners, LLC
iccc@lythampartners.com
602.889.9700